GHDX
GHDX Real Time Price USDRecent trades of GHDX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in GHDX holdings by institutional investors
Quarterly net insider trading by GHDX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$20,000 Jan 20, 2016 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$20,000 Oct 21, 2015 Issue: Health Issues Medical/Disease Research/Clinical Labs
-
$10,000 Jul 30, 2015 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$30,000 Apr 26, 2015 Issue: Medical/Disease Research/Clinical Labs Health Issues
-
$30,000 Jan 19, 2015 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$160,000 Nov 14, 2014 Issue: Health Issues
-
$80,000 Jul 17, 2014 Issue: Health Issues
-
$60,000 Apr 15, 2014 Issue: Health Issues
-
$110,000 Jan 14, 2014 Issue: Health Issues
-
$150,000 Oct 17, 2013 Issue: Health Issues
-
$90,000 Jul 19, 2013 Issue: Health Issues
-
$195,000 Apr 22, 2013 Issue: Health Issues
-
$90,000 Apr 22, 2013 Issue: Health Issues
-
$180,000 Oct 26, 2012 Issue: Health Issues
-
$30,000 Jul 19, 2012 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$60,000 Jul 17, 2012 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
-
$60,000 Apr 19, 2012 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$40,000 Apr 18, 2012 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$20,000 Jan 20, 2012 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$70,000 Jan 10, 2012 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
-
$80,000 Oct 19, 2011 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
-
$40,000 Oct 18, 2011 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$30,000 Jul 19, 2011 Issue: Medicare/Medicaid Health Issues Medical/Disease Research/Clinical Labs
-
$110,000 Jul 05, 2011 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$80,000 Apr 15, 2011 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$110,000 Apr 14, 2011 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
-
$300,000 Jan 19, 2011 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
-
$220,000 Oct 19, 2010 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
-
$250,000 Jul 18, 2010 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
-
$190,000 Apr 19, 2010 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
-
$320,000 Jan 15, 2010 Issue: Medical/Disease Research/Clinical Labs Medicare/Medicaid Health Issues
-
$160,000 Oct 19, 2009 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$400,000 Jul 17, 2009 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$220,000 Apr 17, 2009 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$170,000 Jan 16, 2009 Issue: Medicare/Medicaid Medical/Disease Research/Clinical Labs Health Issues
-
$100,000 Oct 17, 2008 Issue: Health Issues Medicare/Medicaid Medical/Disease Research/Clinical Labs
-
$70,000 Jul 17, 2008 Issue: Medical/Disease Research/Clinical Labs Health Issues Medicare/Medicaid
-
$80,000 Apr 16, 2008 Issue: Health Issues Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$80,000 Mar 26, 2008 Issue: Food Industry (safety, labeling, etc.) Medical/Disease Research/Clinical Labs Medicare/Medicaid
-
$80,000 Aug 02, 2007 Issue: Medical/Disease Research/Clinical Labs
-
$100,000 Mar 15, 2007 Issue: Medical/Disease Research/Clinical Labs
-
$60,000 Aug 15, 2006 Issue: Medicare/Medicaid
GHDX Estimated quarterly lobbying spending
GHDX Revenue by Segment or Geography
New GHDX patent grants
Federal grants, loans, and purchases
- $17,009 2021-10-01 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $0 2021-09-28 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $51,026 2021-09-20 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $100,000 2021-09-08 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $3,193 2021-05-12 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $6,386 2021-05-11 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $3,454 2021-05-11 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $6,386 2021-05-05 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $17,520 2021-04-23 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $124,589 2021-03-18 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $0 2021-03-16 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $86,231 2021-02-11 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $17,270 2021-01-26 00:00:00 Agency: DEPARTMENT OF DEFENSE (DOD)
- $9,965 2021-01-24 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $20,370 2021-01-22 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
- $17,270 2021-01-11 00:00:00 Agency: DEPARTMENT OF VETERANS AFFAIRS (VA)
Estimated quarterly amount awarded to GHDX from public contracts
Recent insights relating to GHDX
Recent picks made for GHDX stock on CNBC
ETFs with the largest estimated holdings in GHDX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $GHDX stock a Buy, Sell, or Hold?
- What is the price target for $GHDX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $GHDX stock?
- Who owns the most shares of $GHDX stock?
- What funds own $GHDX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view GHDX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
No description available